Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
8
self-reported band not used
Founded
2022
4 years
Legal entities
1
ACRA
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
AXCYNSIS THERAPEUTICS PTE. LTD.Entity record →
UEN202205879C
Legal entities
Show as table · Axcynsis Therapeutics: 1 registry entity
| AXCYNSIS THERAPEUTICS PTE. LTD. | UEN 202205879C |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions.
At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs.
With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics.
Based in Singapore, we plan to expand our clinical development operations to the United States by 2024.
Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.
Related specialties
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG41 Science Park Road; Singapore, 117610Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Axcynsis Therapeutics?
One Singapore entity on ACRA. AXCYNSIS THERAPEUTICS PTE. LTD. (UEN 202205879C), high confidence.
How many people work at Axcynsis Therapeutics?
The record holds 8 counted staff profiles at January 2026. Its self-reported band sits above that count and is not published as a headcount.
Where does Axcynsis Therapeutics have offices?
One address on record, Singapore only. Primary: 41 Science Park Road, Singapore 117610.
Has Axcynsis Therapeutics raised funding?
None linked to this brand.
What does Axcynsis Therapeutics list as its specialties?
Five tags on the brand's own list, among them chemistry.
Which companies are listed alongside Axcynsis Therapeutics?
9 profiles list Axcynsis Therapeutics as a peer — 79th percentile in Biotechnology Research. It lists ten peers of its own. Ligature Therapeutics and Singzyme list it back.